Investigational drug · Phase 3
Odronextamab
Also called: REGN1979, Ordspono, R1979
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed/Refractory Follicular Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
17
Any phase or sponsor naming "Odronextamab"
First trial start
2019
Nov 13, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Odronextamab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Follicular Lymphoma (FL)
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Relapsed/Refractory Follicular Lymphoma
- Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
- Diffuse Large B-cell Lymphoma (DLBCL)
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- B-Cell Non-Hodgkin Lymphoma (B-NHL)
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Odronextamab" as an intervention, largest first.
- A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06091865 · 904 participants (planned) · Start Dec 13, 2023 · Primary completion Mar 30, 2028
Drug: Odronextamab; Rituximab and 4 more · For: Diffuse Large B-cell Lymphoma (DLBCL)
Sites: Scottsdale, Arizona; Los Angeles, California; Orange, California · 195 sites in all
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06091254 · 822 participants (planned) · Start Dec 12, 2023 · Primary completion Feb 29, 2028
Drug: Odronextamab; Rituximab and 5 more · For: Follicular Lymphoma (FL)
Sites: Tucson, Arizona; Los Angeles, California; Orange, California · 190 sites in all
- A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular LymphomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06097364 · 733 participants (planned) · Start Nov 14, 2023 · Primary completion Jul 29, 2029
Drug: Odronextamab; Rituximab and 4 more · For: Follicular Lymphoma (FL)
Sites: Plantation, Florida; Noblesville, Indiana; Wichita, Kansas · 145 sites in all
- A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06149286 · 580 participants (planned) · Start Dec 28, 2023 · Primary completion Apr 30, 2031
Drug: Odronextamab; Lenalidomide and 1 more · For: Relapsed/Refractory Follicular Lymphoma; Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Sites: Los Angeles, California; Plantation, Florida; Indianapolis, Indiana · 172 sites in all
- A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03888105 · 515 participants · Start Nov 13, 2019 · Primary completion Jun 17, 2026
Drug: Odronextamab · For: B-cell Non-Hodgkin Lymphoma (B-NHL)
Sites: Chicago, Illinois; Iowa City, Iowa; Louisville, Kentucky · 119 sites in all
- A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06230224 · 216 participants · Start Feb 15, 2024 · Primary completion May 29, 2028
Drug: Odronextamab; Ifosfamide and 7 more · For: B-Cell Non-Hodgkin Lymphoma (B-NHL)
Sites: Ciudad Autonoma de Buenos Aires, Argentina; La Plata, Argentina; San Juan Bautista, Argentina · 81 sites in all
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaPivotal-lookingRecruiting
University of BirminghamAcademic, hospital or other
NCT05991388 · 210 participants (planned) · Start May 2, 2024 · Primary completion May 1, 2031
Drug: Odronextamab; Loncastuximab tesirine and 7 more · For: B-cell Non Hodgkin Lymphoma
Sites: Sydney, Australia; Brisbane, Australia; Perth, Australia · 11 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT02290951 · 200 participants · Start Jan 9, 2015 · Primary completion Aug 21, 2025
Drug: Odronextamab multiple dose levels; Odronextamab multiple dose levels · For: Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia
Sites: Orange, California; Stanford, California; Tampa, Florida · 22 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05685173 · 107 participants (planned) · Start Apr 20, 2023 · Primary completion Feb 16, 2029
Drug: Odronextamab; REGN5837 · For: B-cell Non-Hodgkins Lymphoma (B-NHL)
Sites: Duarte, California; Santa Monica, California; Louisville, Kentucky · 20 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT02651662 · 105 participants · Start Jan 11, 2016 · Primary completion Apr 29, 2026
Drug: cemiplimab; odronextamab · For: Relapsed/Refractory Aggressive B-Cell Lymphoma
Sites: Baltimore, Maryland; Boston, Massachusetts; Grand Rapids, Michigan · 30 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- CAR-HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B-cell non-Hodgkin lymphoma.
Matasar M, Tucker D, Kim TM, et al. · Br J Haematol 2026
- Odronextamab: a bispecific antibody for follicular lymphoma.
Martín García-Sancho A, Cabero-Martínez A, Gutiérrez NC · Expert Opin Investig Drugs 2026
- CD20 × CD3 Bispecific Antibodies in B-Cell Non-Hodgkin Lymphomas: Current Evidence, Therapeutic Integration, and Future Directions.
Giamaiou P, Fioretzaki R, Vassilakopoulos TP, et al. · Medicina (Kaunas) 2026
- Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study.
Luminari S, Jiménez-Ubieto A, Chong G, et al. · Hemasphere 2026
- Limitations of the epcoritamab vs odronextamab comparative analysis.
Kim TM, Kamat SA · Blood Adv 2026
- Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study.
Villasboas JC, Poon M, Tani M, et al. · Future Oncol 2026
Also in development for Follicular Lymphoma (FL)
- SurovatamigAZD0486, TNB-486Phase 39 trials
AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma
- SCTB35Phase 34 trials
Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, Follicular Lymphoma (FL), System Lupus Erythematosus
- MDX2003Phase 21 trial
ModeX Therapeutics, An OPKO Health Company · Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.